Cancer Nursing Congress Market Analysis and Reports | singapore Conference Series

Market Analysis - Cancer Nursing Congress 2017

Summary of Cancer Nursing Congress 2017:-

Cancer Nursing Congress 2017 welcomes attendees, presenters, and exhibitors from all over the world to Singapore city, Singapore. We are delighted to invite you all to attend and register for the “International Conference on Oncology Nursing and Cancer care “which is going to be held during September 13-14, 2017 in Holiday Inn Atrium, Singapore. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Cancer Nursing Congress 2017, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Cancer Nursing Congress 2017 organizing committee look forward to meeting you in Holiday Inn Atrium, Singapore.

Importance of Cancer/Oncology Nursing:-

Cancer is the second leading cause of death worldwide and in all regions of the world except sub-Saharan Africa. Historically, the UAE had a much lower incidence of cancer than Western countries; however, over the last 40 years, it has undergone a period of dramatic economic, social, and demographic change, resulting in increased life expectancy and prosperity.

The Scope of Cancer Nursing Congress 2017 is to inform the scientific community about all innovative aspects regarding cancer diseases. The participants can gather knowledge about the topics like research findings, cancer preventions, environment and cancer, translational researches, pharmacology and pharmacogenomics aspects, cancer survivorship, cancer treatments, elderly cancer patients, innovative aspects regarding diagnosis, pathology, clinical experimental oncology etc by being a part of this event. It expands knowledge of the members those participating the global conference about different types of cancers like breast cancer, oral cancer, leukemia, skin cancer, colon cancer, rectal colon cancer, cervical cancer, lung cancer, thoracic cancer etc.

In the radiation oncology arena the nurses need to have an understanding of radiobiology and radiation physics. They are also responsible for extensive symptom management, patient education and the submission process for clinical trials or research protocols.

The roles include:

  • Professional practice
  • Critical thinking and analysis
  • Provision and coordination of care
  • Collaborative and therapeutic practice.

Scope and Importance of Cancer Nursing Congress 2017: Why to Attend???

Cancer/Oncology nursing conference is an opportunity to meet others within specialty to network and to learn the latest clinical information. It is an opportunity no nurse should overlook. I’ve always embraced the opportunity to attend nursing conferences and have made a point to encourage others to attend whenever the opportunity arises. Nursing conferences allow nurses of all levels of experience to participate in an area of career and education growth that is not easily found within the structure of the workplace. All too often the floor/ bedside nurse believes that conferences are only for management, while others may think that spending one or more days not earning a pay check may not outweigh the opportunity to clock in some additional overtime. There may be a whole host of other reasons why a nurse would prefer to remain home rather than attending a conference.  Despite the plentiful excuses (the top two being cost and time), the benefits far outweigh the costs. The oncology nurse practices at a high level of autonomy and accountability in collaboration with oncologists and the inter-professional Health-care team to provide a continuum of patient care from prevention, early detection, diagnosis, treatment, follow-up, palliation, bereavement and survivorship.

  • Direct Comprehensive Care
  • Supportive Care
  • Navigating The System
  • Professional Practice
  • Collaborative Practice

Why Singapore?

Though physically small, Singapore is an economic giant. It has been Southeast Asia’s most modern city for over a century. The city blends Malay, Chinese, Arab, Indian and English cultures and religions. Its unique ethnic tapestry affords visitors a wide array of sightseeing and culinary opportunities from which to choose.

Singapore is a popular country for foreign patients seeking medical treatment. Apart from high standard of medical care which is comparable to some of the best hospitals in the world, the cost of treatment at private hospitals is still lower than that at many hospitals in the States and Europe.

In Singapore, it accounts for 29.7% of female cancers and about 1,100 new cases are diagnosed with 270 deaths each year. This translates to about 3 women diagnosed every day and 1 death every other day. Clinical services in Singapore emphasize excellence, safety and trustworthiness, with internationally-accredited facilities and renowned physicians trained in the best centers in the world. Singapore's healthcare system was ranked as the sixth best in the world and the best in Asia by the World Health Organization in 2000. In addition, 13 hospitals and medical centers in Singapore have obtained Joint Commission International (JCI) accreditation.

Target Audience:

  • Academic Research Institutes
  • Hospitals and Clinics
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers and Universities

Societies Associated with Cancer Nursing Congress 2017:-


  • Singapore Cancer Society (SCS)
  • National Cancer Centre Singapore
  • National Council of Social Services
  • Sociology Society(NUS)


  • Asian Society for Neuro-Oncology
  • Asia-Pacific Journal of Clinical Oncology
  • Australasian Lung Cancer Trials Group
  • Cancer Therapeutics Research Group
  • Asian Society of Gynaecologic Oncology
  • Asia-Oceana Research Organization on Genital Infection and Neoplasia
  • Argentina Coloproctology Society


  • Society for Women's Health Research
  • European Association for Cancer Research (EACR)
  • American Cancer Society
  • Spanish Association for Cancer Research (CMA)
  • Association of Women's Health, Obstetric and Neonatal Nurses New Zealand Breast Cancer Foundation (NZBCF)
  • International Association for Women's Mental Health
  • Association of Chartered Physiotherapists in Women’s Health
  • American Medical Women's Association
  • Caribbean Women's Health Association

Universities in Singapore:-

  • National University of Singapore  
  • National University Cancer Institute, Singapore
  • Nanyang Technological University  
  • Singapore Management University    SMU
  • Singapore Polytechnic    SP
  • Singapore University of technology  SIT
  • Jamescook University

Universities in Asia:-

  • The University of Tokyo
  • National University of Singapore (NUS)
  • Kyoto University
  • University of Hong Kong (HKU)
  • Peking University
  • Seoul National University (SNU)
  • National Taiwan University (NTU)
  • Osaka University
  • Tsinghua University
  • The Chinese University of Hong Kong (CUHK)

Universities in World Wide:-

  • Hospital of the University of PA – Abramson Cancer Center
  • Roswell Park Cancer Institute
  • Johns Hopkins Hospital Sidney Kimmel Comprehensive Cancer Center
  • University of Texas M.D. Anderson Cancer Center
  • Spanish National Cancer Research Center
  • Oceania Oncology Netherlands Cancer Institute
  • Vall D’Hebron Institute of Oncology

Industries Associated with Cancer Research


  • Roche
  • Novartis        
  • Celgene          
  • Johnson & Johnson  
  • Bristol-Myers Squibb           
  • Lilly    
  • Takeda          
  • AstraZeneca  
  • Merck & Co.  
  • Amgen                       
  • Pfizer             

Market growth of Cancer/Oncology Nursing Care Research in the last and upcoming ten years:

The global Oncology/Cancer Nursing market has experienced substantial growth over the last couple of years. This market is expected to grow at a CAGR of 11.6% from 2015 to 2020. The global Cance0072 Profiling market is poised to reach USD 61.87 Billion by 2021 from USD 25.82 Billion in 2016, at a CAGR of 19.1% from 2016 to 2021. Factors such as rising incidence of cancer; technological advancements in omics technologies; favorable government funding for cancer research; increased demand for personalized medicines in cancer therapies; and increased use of biomarkers in drug discovery development and clinical trials are expected to fuel the growth of the cancer biomarkers market during the forecast period. However, poorly suited regulatory and reimbursement systems of biomarker tests, high capital investments for biomarker discovery and development, and sample collection and storage difficulties are restraining the growth of this market.

The past three decades have witnessed a remarkable growth in nursing Care development. In both Korea and the United States, nurse scientists are poised to address important issues related to the prevention and management of significant health care problems. The need for greater nursing Care development in the areas of self-management, genetics, and geriatrics, health promotion across the lifespan, technology, and mental health are briefly highlighted. Future research efforts will be enhanced by interdisciplinary collaboration and the creation of international nursing research centers. At the same time, we need to remain cognizant of the importance of mentoring future nursing Care.

Competitive Market Share Insights:

  • Abbott Laboratories
  • Affymetrix Inc.
  • Roche Diagnostics Ltd.
  • Illumina, Inc.
  • Qiagen NV
  • Agilent Technologies
  • Thermo Fisher Scientific Inc.
  • Merck & Co. Inc.
  • Becton Dickinson and Company
  • Hologic Inc. (U.S.).

Registered Doctors: 15,000 (in thousands)

Singapore: 11,733

Worldwide: 20380 (in thousands)

Registered Nurses: 1,000 (in thousands)

Singapore: 27,556

Worldwide: 20380 (in thousands)

Market Insights:

The Asia-Pacific market is poised to register the highest growth rate in the forecast period owing to the favorable government funding for cancer biomarker research, rising prevalence of cancer, increasing demand for advanced healthcare facilities in developing economies such as India, Singapore and China, increasing number of clinical trials, and increasing focus of international players in emerging markets. The global cancer biomarkers market is consolidated in nature at the top. In order to maintain their market shares, leading players are continuously focusing on new product developments and upgrading their existing products to enhance their product portfolios. Increasing competition among major players is expected to drive innovation in the market, thereby helping the industry to overcome existing challenges in various applications such as diagnostics, drug discovery and development, personalized medicine, among others.

As per the market report most of the Oncology companies mainly invests in the following:

  • Cancer Vaccines
  • Biopsy Devices
  • Biological Therapies for Cancer Treatment

Cancer Vaccines

The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound annual growth rate (CAGR) of 1.3% for the period 2014-2019. The United States as a segment will grow from about $1.9 billion in 2014 to $2 billion by 2019 at a 1.9% CAGR for the period 2014-2019. Europe as a segment will grow from $1.0 billion in 2014 to $1.2 billion in 2019, increasing at a CAGR of 3.5% from 2014-2019.The global market for solid organ preservation solutions totaled $459 million in 2014. This market is estimated to grow at a CAGR of 12.9% to reach $582.5 million by 2015 and nearly $1.1 billion by 2020.

Biopsy Devices:-

The global market for biopsy devices should reach around roughly $2.1 billion by 2020 from over $1.5 billion in 2015, a compound annual growth rate (CAGR) of 6.2% from 2015 to 2020. The North American market should reach $868.8 million by 2020 from $663.9 million in 2015, at a CAGR of 5.5% from 2015 to 2020. The European market should reach $785.3 million by 2020 from $586.0 million in 2015, at a CAGR of 6.0% from 2015 to 2020. The global market for alternative technologies used in organ and tissue transplantation in 2014 totaled $30.5 billion. This market is estimated to grow at a CAGR of 4.6% from 2015 to 2020 to reach nearly $33.3 billion in 2015 and $41.6 billion by 2020.

Biological Therapies for Cancer Treatment:-

The global market for biologic cancer treatment totaled $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019. Monoclonal antibodies as a segment will grow from around $28.5 billion in 2014 to about $37.3 billion by 2019 at a 5.6% CAGR for the period 2014-2019.Immunostimulants as a segment will grow from $14.8 billion in 2014 to $18.5 billion in 2019, increasing at a CAGR of 4.6% from 2014-2019.

Fund Allotment to Cancer/Oncology Research

Since its inception in 1998, funds raised in a variety of ways provide support for specific cancer research and public education projects. The fund was renamed in year 2011 to better reflect its purpose with a strong focus on optimizing patient care. With your help, more lives can be touched as cancer affects 1 in 3 here. Financial assistance can help to diminish some distress that they experience from challenges that they may face along their cancer journey.